KineMed to price IPO of 4.05 million shares between $6.50 and $7.50

Feltl, MLV and Laidlaw to assist with initial offering of common stock

By Devika Patel

Knoxville, Tenn., June 9 – KineMed, Inc. will sell 4.05 million common shares in its initial public offering with a 30-day greenshoe of 675,000 additional shares, according to a Form S-1/A filed Monday with the Securities and Exchange Commission. The deal was announced Jan. 8.

Feltl and Co. is the bookrunning manager. MLV & Co. and Laidlaw & Co. (UK) Ltd. are the co-managers.

Proceeds will be used for the start-up and development of a laboratory, clinical trials, sales, marketing and business development, working capital and general corporate purposes.

The Emeryville, Calif., company plans to collaborate with pharmaceutical and biotechnology companies to develop diagnostic biomarker tests. It intends to list its common stock on the Nasdaq under the symbol “KNMD.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.